SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Sycamore who wrote (5673)2/26/1998 2:31:00 PM
From: Richard Singer  Read Replies (1) | Respond to of 23519
 
Off topic:

Macrochem is still in Phase IIB testing which must be completed, of course, before they proceed to Phase III. No immediate marketing threat to VVUS, but their SEPA technology is an interesting story, anyhow, for more than just ED usage.

I bought MCHM at 6 3/4 on the same day that I repurchased VVUS at 20 1/2 (ouch)- the day before the crash. MCHM has had a good run of late, with receipt of a NASDAQ listing, the commencement of option trading on the AMEX and CBOE and has encountered some heavy "sell on the news" profit-taking today. I tried and failed to do so myself - too greedy.

Richard



To: Sycamore who wrote (5673)2/26/1998 2:38:00 PM
From: Gene Voss  Read Replies (2) | Respond to of 23519
 
SYCAMORE:Topically applied versions are a dream that won't be approved.
This entire ED debate has deteriorated into a snake oil deal with every pseudoscientific permutation imaginable.The band wagon is small but the fight to jump on is fierce.The APPARENT simplicity of the science coupled with the dubious end points and complex patient mix will allow many opportunities for fraud and deception

GV.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News